Abstract: Slide Presentations |

Cardiovascular Morbidity and Mortality among Persons with Chronic Obstructive Pulmonary Disease (COPD) FREE TO VIEW

Cynthia de Luise, RPA-C, MPH*; Stephan F. Lanes, PhD; Stephen Sidney, MD, MPH; Charles P. Quesenberry, Jr., PhD; Mark Eisner, MD, PhD
Author and Funding Information

Pfizer, Inc., New York, NY


Chest. 2004;126(4_MeetingAbstracts):739S. doi:10.1378/chest.126.4_MeetingAbstracts.739S
Text Size: A A A
Published online


PURPOSE:  The magnitude of increased risk for cardiovascular disease (CVD) among persons with COPD is uncertain. The purpose of this study was to assess the risk of CVD among persons diagnosed and treated for COPD.

METHODS:  A cohort study was conducted using the Northern California Kaiser Permanente Medical Care Program (KPMCP) among persons >=40 years old who were diagnosed with COPD from January 1996 to December 1999, and who received >=2 prescriptions for a bronchodilator within 6 months of diagnosis. Subjects were matched by age, gender and duration of plan membership to a randomly selected control without COPD. COPD diagnosis, selected CV outcomes and smoking behavior were validated through chart review and a survey administered to a subset of participants. Prevalence of CV risk factors and conditions, and incidence of CVD were measured. Odd ratios for prevalence, risk ratios for incidence and 95% confidence intervals were estimated.

RESULTS:  Subjects with COPD (n=45,966) constituted 3.7% of the eligible population; 25,468 (55%) male and 20,498 (45%) female. The mean age was 64 years; 15% were <50 years; almost half the cohort was <65 years and 10% were >=80 years old. During an average follow-up period of three years, incidence of any hospitalization for CV causes in COPD subjects was elevated compared to controls (RR=2.3, 95% CI 2.2, 2.4), as were cause-specific hospitalizations for CV conditions. Subjects with COPD were more likely to die from all causes (RR=3.4, 95% CI 3.3, 3.6), from CV-related causes combined (RR=2.4, 95% CI 2.2, 2.5), and from major cause-specific CV conditions: congestive heart failure (RR=4.9, 95% CI 3.4, 7.2), acute myocardial infarction (RR=2.3, 95% CI 2.0, 2.7), stroke (RR=1.5, 95% CI 1.2, 1.8), pulmonary embolism (RR=2.4, 95% CI 1.2, 4.7) and atrial fibrillation (RR=1.6, 95% CI 0.3, 9.6).

CONCLUSION:  Persons with diagnosed and treated COPD had approximately two to threefold increased risk of hospitalizations and deaths due to CVD.

CLINICAL IMPLICATIONS:  Persons with diagnosed and treated COPD have an increased risk of hospitalizations and deaths due to CVD.

DISCLOSURE:  C. de Luise, Boehringer Ingelheim and Pfizer

Tuesday, October 26, 2004

10:30 AM- 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543